June 2026 cbdMD, Inc. announced the successful integration of Bluebird Botanicals following its acquisition, expanding its consumer health portfolio of CBD tinctures, capsules, topicals, and wellness products while strengthening its retail and e-commerce presence.
June 2026 Red White & Bloom Brands, through its subsidiary Emblem Cannabis Corporation, completed the acquisition of Ayurcann's Health Canada-licensed manufacturing operations, including vape brands, manufacturing assets, and expanded national distribution capabilities, reinforcing its cannabinoid consumer health business.
September 2025 The UK Food Standards Agency (FSA) launched a consultation on the authorization of CBD novel food products, advancing the regulatory pathway for cannabidiol consumer health products and establishing updated labeling and safety requirements for the UK market.
July 2025 Ananda Pharma initiated its Phase I clinical trial for MRX1, a cannabidiol (CBD)-based drug candidate, expanding its R&D pipeline and supporting the broader development of cannabidiol-based consumer and therapeutic health products.